Experimental exon-skipping drug from Avidity Biosciences shows early improvement in a Duchenne patient

A recent story follows two teenage boys living with Duchenne muscular dystrophy, a rare and fatal muscle‑wasting condition. While one boy’s health continues to decline, the other, a 12‑year‑old named Brecken, has begun to improve after starting an experimental therapy.

Brecken’s treatment is an exon‑skipping drug developed by Avidity Biosciences. The medicine is designed to make the cell’s protein‑building machinery skip over faulty sections of the dystrophin gene, potentially restoring some muscle function. Early observations suggest Brecken’s condition is stabilizing and even showing signs of progress.

The case highlights the broader challenge of delivering novel therapies for rare diseases. Exon‑skipping drugs are a focal point for the FDA as it seeks to encourage innovative treatments for conditions like Duchenne, but access remains limited to a small number of patients at this stage.